Table 3 Association between H3Cit, IL-18, CRP, and ICI response (univariable and multivariable competing-risk regression models)

Age, year <48/≥48

1.046(1.007–1.086)

0.020

Sex

 Male/Female

0.846(0.422–1.693)

0.636

ECOG score

 0/1

1.066(0.413–2.751)

0.896

Smoking

 Yes/No

0.482(0.191–1.216)

0.122

Alcohol

 Yes/No

0.914(0.287–2.907)

0.879

Tumor classification

 Lung cancer/Nasopharyngeal carcinoma/Gastrointestinal tumors/Melanoma

0.673(0.418–1.083)

0.103

Stage

 III/IV

1.568(0.651–3.778)

0.316

Distant metastasis sites

 Lung

1.667(0.286–9.708)

0.570

 Liver

0.799(0.273–2.336)

0.682

 Bone

2.571(0.534–12.378)

0.239

 Other

1.733(0.403–7.462)

0.460

No. of metastatic sites

 <2/≥2

0.602(0.227–1.594)

0.307

Combination therapy

 Yes/No

1.524(0.497–4.667)

0.461

H3Cit (ng/mL)

 <12.11/≥12.11

11.393(3.874–33.503)

0.000

31.343(4.871-201.663)

0.000

IL-8 (pg/mL)

 <221.88/≥221.88

8.857(3.027–25.918)

0.000

14.116 (2.071–96.207)

0.007

IL-18 (pg/mL)

 <201.48/≥201.48

1.000(1.000–1.000)

0.486

IL-18BP (pg/mL)

 < 98.78/≥98.78

1.000(0.998–1.001)

0.596

WBC (10⁹/L)

 <5.80/≥5.80

2.912(1.191–7.121)

0.019

NEU (10⁹/L)

 <4.44/≥4.44

2.076(0.851–5.064)

0.108

LYM (10⁹/L)

 <1.94/≥1.94

1.371(0.617–3.047)

0.439

MO (10⁹/L)

 <0.44/≥0.44

2.462 (1.009–6.009)

0.048

EO (10⁹/L)

 <0.06/≥0.06

1.395E9(0.000-)

0.999

PLT (10⁹/L)

 <235.0/≥235.0

1.391(0.569–3.402)

0.469

NLR

 <3.98/≥3.98

1.935(0.722–5.188)

0.189

LMR

 <4.74/≥4.74

1.879(0.670–5.269)

0.231

PLR

 <223.58/≥223.58

1.605(0.655–3.930)

0.713

ALB (g/L)

 <41.95/≥41.95

0.222(0.087–0.563)

0.002

GLB (g/L)

 <38.23/≥38.23

0.588(0.122–2.837)

0.508

CRP (mg/L)

 <14.19/≥14.19

8.910(2.954–26.877)

0.000

11.751(1.542–89.539)

0.017

SAA (mg/L)

 <12.95/≥12.95

5.558(2.041–15.137)

0.001